Logo

Orchid Cellmark Shares Up 16 Percent Despite Wider Q2 Losses and Revenue Decline

Aug 08, 2006
NEW YORK (GenomeWeb News) - Shares in Orchid Cellmark were up approximately 16 percent, or $.33, at $2.45 in mid-afternoon trading today despite the company’s 14-percent decline in revenues and second-quarter loss.
 
As GenomeWeb News reported this morning, Orchid today posted a 14-percent decline in revenues amid mounting losses for the second quarter.
Breaking News
The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.